AllyxThera
  • Home
  • About Us
  • Our Science
  • News and Events
  • Careers
  • Contact
Select Page

Allyx sets Phase II plans for AD in motion after Phase Ia

by Tim Siegert | Oct 31, 2023 | News | 0 comments

Recent Posts

  • Yale’s Adam Mecca, MD, PhD Discusses ALX-001 with NeurologyLive
  • Allyx sets Phase II plans for AD in motion after Phase Ia
  • Oral ALX-001 Achieves Full Brain Receptor Occupancy
  • ALX-001 Phase 1 Presentation at CTAD
  • NIA Small Business Showcase: Allyx Therapeutics, Inc.

Menu

  • Home
  • About Us
  • Our Science
  • News and Events
  • Careers
  • Contact

Contact

Allyx Therapeutics, Inc.
555 Long Wharf Drive
Floor 11
New Haven, CT 06511

info@allyxthera.com

Social

Copyright © 2023Allyx Therapeutics, Inc.